How Trump's tariffs are reshaping Indian pharma
· livemint.com
US tariffs may not impact Indian pharma in the short term, but building replacement capacity on US soil remains cost-prohibitive for thin-margin producers. At the same time, a Deloitte survey reveals CXOs want to prioritize specialty expansion.
Generics challenge
After President Trump’s 22 July announcement, the Nifty Pharma index fell 1.31%, with 18 of its 20 stocks closing lower. Since then, there...